Catalyst Pharmaceutical Partners, Inc.
As
filed with the Securities and Exchange Commission on June 2, 2008
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
CATALYST PHARMACEUTICAL PARTNERS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
|
|
76-0837053 |
|
(State or Other Jurisdiction
|
|
(I.R.S. Employer |
of Incorporation or Organization)
|
|
Identification Number) |
355 Alhambra Circle
Suite 1370
Coral Gables, Florida 33134
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive
Offices)
Patrick J. McEnany
355 Alhambra Circle
Suite 1370
Coral Gables, Florida 33134
(305) 529-2522
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
Copy to:
Philip B. Schwartz, Esq.
Akerman Senterfitt
One Southeast Third Avenue
Suite 2500
Miami, Florida 33131
(305) 374-5600
Approximate date of commencement of proposed sale to the public: From time to time after the
effective date of this Registration Statement.
If the only securities being registered on this form are being offered pursuant to dividend or
interest reinvestment plans, please check the following box. o
If any of the securities being registered on this form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, check the following
box.
þ
If this Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities
Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. o
If this Form is a registration statement pursuant to General Instruction I.D. or a
post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box. o
If this Form is a post-effective amendment to a registration statement filed pursuant to
General Instruction I.D. filed to register additional securities or additional classes of
securities pursuant to Rule 413(b) under the Securities Act, check the following box. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company. See the
definitions of large accelerated filer, accelerated
filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer
o
|
|
Non-accelerated filer o
|
|
Smaller reporting company
þ |
|
|
|
|
(Do not check if a smaller reporting company) |
|
|
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed |
|
|
|
|
|
|
|
|
|
|
|
Amount to be |
|
|
Maximum |
|
|
Proposed Maximum |
|
|
Amount of |
|
|
|
|
|
Registered |
|
|
Offering Price |
|
|
Aggregate Offering |
|
|
Registration |
|
|
Title of Each Class of Shares to be Registered |
|
|
(3) |
|
|
Per Share |
|
|
Price (1) (2) |
|
|
Fee |
|
|
Common Stock, par value $0.001 per share |
|
|
(4) |
|
|
|
(4 |
) |
|
|
$ |
30,000,000 |
|
|
|
$ |
1,179.00 |
|
|
|
(1) |
|
The proposed maximum offering price per security will be determined from time-to-time by the
Registrant in connection with the issuance of the securities registered by this registration
statement |
|
(2) |
|
Estimated solely for the purpose of calculating the Registration Fee. At no time will the
aggregate maximum offering price of all securities issued in any given 12-month period exceed the
amount allowed for in General Instruction I.B.6. |
|
(3) |
|
Subject to the restrictions of Rule 4350 of the Nasdaq Marketplace Rules, the Registrant may
sell only 20% of its shares in a primary offering in any given year if such shares are sold below
market value. |
|
(4) |
|
To be set forth in future supplements to this Prospectus. |
The Registrant hereby amends this registration statement on such date or dates as may be necessary
to delay its effective date until the registrant shall file a further amendment that specifically
states that the registration statement shall thereafter become effective in accordance with Section
8(a) of the Securities Act of 1933 or until the registration statement shall become effective on
such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a) may
determine.
The information in this prospectus is not complete and may be changed. These securities may not be
sold until the Registration Statement containing this prospectus, which was filed with the
Securities and Exchange Commission, is effective. The prospectus is not an offer to sell these
securities and it is not soliciting an offer to buy these securities in any state where the offer
or sale is not permitted.
SUBJECT
TO COMPLETION, DATED JUNE 2, 2008
PROSPECTUS
$30,000,000
Common Stock
We may, from time to time, sell shares of our common stock in one or more offerings in
amounts, at prices and on terms that we determine at the time of the offering, with an aggregate
initial offering price of up to $30,000,000. We will provide you of the specific terms of such
securities in supplements to this prospectus. However, in no event will we sell securities with a value exceeding more than 1/3 of
our public float in any 12-month period. You should read this prospectus and any prospectus
supplement carefully before you invest.
INVESTING IN OUR SECURITIES INVOLVES RISKS. THE RISKS ASSOCIATED WITH AN INVESTMENT IN OUR
SECURITIES WILL BE DESCRIBED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND IN OUR FILINGS WITH THE
SECURITIES AND EXCHANGE COMMISSION THAT ARE INCORPORATED BY REFERENCE HEREIN, ALL AS MORE
PARTICULARLY DESCRIBED UNDER THE CAPTION RISK FACTORS ON PAGE 4 OF THIS PROSPECTUS.
Our common stock is listed on the Nasdaq Global Market and trades under the symbol CPRX. On
May 30, 2008, the last reported sale price for our common stock on the Nasdaq Global Market was
$3.59 per share.
The common stock may be sold by us to or through underwriters or dealers, directly to
purchasers or through agents designated from time to time. For additional information on the
methods of sale, you should refer to the section entitled Plan of Distribution in this
prospectus. If any underwriters are involved in the sale of any common stock with respect to which
this prospectus is delivered, the names of such underwriters and any applicable discounts or
commissions, and any over-allotment options will be set forth in a prospectus supplement. The price
to the public and the net proceeds we expect to receive from such sale will also be set forth in
the prospectus supplement.
Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of the common stock or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2008.
ABOUT THIS PROSPECTUS
This
prospectus is part of a registration statement that we have filed with the Securities and
Exchange Commission (the SEC), utilizing a shelf registration process. Under this shelf
registration process, we may sell shares of our common stock in one or more offerings up to a
total dollar amount of $30,000,000. However, in no event will we sell securities with a value exceeding more than 1/3 of our public
float" (the market value of our common stock held by non-affiliates) in any 12 month period. This
prospectus provides you with a general description of our common stock. Each time we sell
securities under this shelf registration, we will provide a prospectus supplement that will contain
specific information about the terms of the applicable offering. The prospectus supplement may also
add, change, or update information contained in this prospectus. You should read both this
prospectus and any prospectus supplement, together with any additional information described under
the heading Incorporation by Reference.
We have not authorized any dealer, salesperson or other person to give any information or to
make any representation other than those contained or incorporated by reference in this prospectus
and any accompanying supplement to this prospectus. You must not rely upon any information or
representation not contained or incorporated by reference in this prospectus or any accompanying
prospectus supplement. This prospectus and any accompanying supplement to this prospectus do not
constitute an offer to sell or the solicitation of an offer to buy any securities other than the
registered securities to which they relate, nor do this prospectus and any accompanying supplement
to this prospectus constitute an offer to sell or the solicitation of an offer to buy securities in
any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such
jurisdiction. You should not assume that the information contained in this prospectus and any
accompanying prospectus supplement is accurate on any date subsequent to the date set forth on the
front of the document or that any information we have incorporated by reference is correct on any
date subsequent to the date of the document incorporated by reference, even though this prospectus
and any accompanying prospectus supplement is delivered or securities are sold on a later date.
Reference in this prospectus to we, our, us, the Company, or Catalyst refer to
Catalyst Pharmaceutical Partners, Inc., a Delaware corporation.
ABOUT THE COMPANY
We are a development-stage biopharmaceutical company focused on the acquisition, development
and commercialization of prescription drugs for the treatment of drug addiction and obsessive
compulsive disorders. Our initial product candidate is CPP-109, which is our version of vigabatrin.
The successful development of CPP-109 or any other product we may develop, acquire, or license
is highly uncertain. We cannot reasonably estimate or know the nature, timing, or estimated
expenses of the efforts necessary to complete the development of, or the period in which material
net cash inflows are expected to commence due to the numerous risks and uncertainties associated
with developing, such products, including the uncertainty of:
|
|
|
the scope, rate of progress and expense of our clinical trials and our other product
development activities; |
|
|
|
|
the results of future clinical trials, and the number of clinical trials (and the
scope of such trials) that will be required to seek and obtain approval of a New Drug
Application (NDA) for CPP-109; and |
1
|
|
|
the expense of filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights. |
Our principal executive offices are located at 355 Alhambra Circle, Suite 1370, Coral Gables,
Florida 33134. Our telephone number is (305) 529-2522. Our website is
http://www.catalystpharma.com. The information contained in, or that can be accessed
through, our website is not a part of this prospectus.
Recent Developments
U.S. Phase II clinical trial for cocaine addiction
During July 2007, we initiated a randomized, double-blind, placebo-controlled U.S. Phase II
clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. We estimate that the cost of this trial will be approximately $6,000,000.
The trial is expected to enroll 180 cocaine addicted patients at not less than 11 addiction
treatment clinical centers in the United States. Patients will be treated for a period of 12 weeks,
with an additional 12 weeks of follow-up. The primary endpoint of the trial is to demonstrate that
a larger proportion of CPP-109-treated subjects than placebo-treated subjects will be cocaine-free
during their last two weeks of treatment (weeks 11 and 12). Additionally, we will be measuring
several secondary endpoints based on reductions of cocaine use and craving. To be eligible to
participate in this trial, participants must meet specific clinical standards for cocaine
dependence, as specified in DSM-IV, a set of diagnosis guidelines established for clinical
professionals. Additionally, trial participants cannot meet the DSM-IV criteria for dependence on
most other addictive substances. Further, eye safety studies will be conducted on all trial
participants before and after the trial to determine the extent of visual field defects that may
occur as a result of the trial among such participants, if any. We began enrolling patients in this
trial in January 2008 after the protocol for our trial was accepted by the U.S. Food and Drug
Administration (FDA). Based on currently available information, we expect to have initial
top-line results from this trial in the fourth quarter of 2008. However, the date we obtain the
results from our study will ultimately depend on the timing of patient enrollment into our study,
which cannot be predicted with absolute certainty. Additional information about our trial can be
found at www.clinicaltrials.gov.
U.S. Phase II clinical trial for methamphetamine addiction
We
expect to initiate during the second quarter of 2008 a 180 patient randomized, double-blind, placebo-controlled U.S.
Phase II clinical trial evaluating the use of CPP-109 in treating patients with methamphetamine
addiction. This trial will be similar to our cocaine trial. We currently estimate that the cost of this trial will
be approximately $5,900,000. Based on currently available information, we expect to have initial
top-line results from this trial during the third quarter of 2009.
2
Contemplated pilot clinical trials
We hope to initiate during 2008 a Phase II clinical trial evaluating CPP-109 for the treatment
of binge eating disorder. We are also contemplating and hope to launch during 2008 additional Phase
II proof-of-concept trials evaluating the use of CPP-109 for the treatment of other addictions,
including alcohol and nicotine.
Discussions with strategic partners
We
have had in the past, and expect to continue to have in the future, discussions with potential strategic partners interested in working with
us on the development of CPP-109. No agreements have been entered into to date with
any potential strategic partners.
3
INFORMATION REGARDING FORWARD LOOKING STATEMENTS
Some of the statements provided in or incorporated by reference by this prospectus contain
forward-looking statements, including statements regarding our expectations, beliefs, plans or
objectives for future operations and anticipated results of operations. For this purpose, any
statements contained herein that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the words, believes, anticipates,
proposes, plans, expects, intends, may and similar expressions are intended to identify
forward-looking statements. Such statements involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by such
forward-looking statements. The forward-looking statements made in this prospectus are based on
current expectations that involve numerous risks and uncertainties, including but not limited to
the following:
|
|
our having sufficient financial resources and the ability to successfully complete the
clinical trials required for us to file an NDA for CPP-109; |
|
|
|
our ability to complete our clinical trials on a timely basis and within the budgets we establish
for such trials; |
|
|
|
our ability to protect our intellectual property; |
|
|
|
whether others develop and commercialize products competitive to our products; |
|
|
|
changes in the regulations affecting our business; |
|
|
|
our ability to attract and retain skilled employees; and |
|
|
|
changes in general economic conditions and interest rates. |
Our current plans and objectives are based on assumptions relating to the development of our
business. Although we believe that our assumptions are reasonable, any of our assumptions could
prove inaccurate. In light of the significant uncertainties inherent in the forward-looking
statements made herein, which reflect our views only as of the date of this prospectus, you should
not place undue reliance upon such statements. We undertake no obligation to update or revise
publicly any forward-looking statements, whether as a result of new information, future events or
otherwise.
RISK FACTORS
Before making an investment decision, you should carefully consider the risks described under
Risk Factors in the applicable prospectus supplement and in our most recent Annual Report on Form
10-K, or any updates in subsequent Quarterly Reports on Form 10-Q, together with all of the other
information appearing in this prospectus or incorporated in this prospectus by reference and any
applicable prospectus supplement, in light of your particular investment objectives.
4
USE OF PROCEEDS
Except as may otherwise be provided in a prospectus supplement, we will use the net proceeds
from the sale of the securities to fund a Phase III clinical trial evaluating the use of CPP-109 to
treat cocaine addiction, to fund additional clinical trials required to allow us to file an NDA for cocaine addiction, to fund additional clinical trials
evaluating the use of CPP-109 to treat other addictions or obsessive compulsive disorders, and for general corporate purposes. When
particular securities are offered, the prospectus supplement relating to that offering will set
forth our intended use of the net proceeds received from the sale of these securities. Pending the
application of the net proceeds for these purposes, we expect to invest the proceeds in short-term,
interest-bearing instruments or other investment-grade securities.
PRICE RANGE OF COMMON STOCK AND DIVIDEND POLICY
Since November 8, 2006, our common stock has been traded on the Nasdaq Global Market under the
symbol CPRX. Prior to such date, there was no market for our common stock. The last reported sale
price of our common stock on May 30, 2008 on the Nasdaq
Global Market was $3.59 per share. The
following table sets forth the high and low sale prices for our common stock for the periods
indicated as reported on the Nasdaq Global Market.
|
|
|
|
|
|
|
|
|
|
|
High |
|
Low |
Year Ended December 31, 2006 |
|
|
|
|
|
|
|
|
Fourth Quarter (from November 8, 2006) |
|
$ |
6.15 |
|
|
$ |
4.25 |
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2007 |
|
|
|
|
|
|
|
|
First Quarter |
|
$ |
6.83 |
|
|
$ |
3.80 |
|
Second Quarter |
|
$ |
4.65 |
|
|
$ |
3.48 |
|
Third Quarter |
|
$ |
4.00 |
|
|
$ |
2.70 |
|
Fourth Quarter |
|
$ |
3.51 |
|
|
$ |
2.50 |
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2008 |
|
|
|
|
|
|
|
|
First Quarter |
|
$ |
3.87 |
|
|
$ |
2.94 |
|
Second Quarter (through May 30, 2008) |
|
$ |
3.99 |
|
|
$ |
3.30 |
|
We have never declared or paid any cash dividends on our capital stock. We currently intend to
retain all available funds and any future earnings to support operations and finance the growth and
development of our business and do not intend to pay cash dividends on our common stock for the
foreseeable future. Any future determination related to our dividend policy will be made at the
discretion of our Board of Directors.
5
GENERAL DESCRIPTION OF OUR COMMON STOCK
The following summary of the material features of our common stock does not purport to be
complete and is subject to, and qualified in its entirety by the provisions of our Certificate of
Incorporation, our Bylaws and other applicable law. See Where You Can Find Additional
Information.
Our authorized capital currently consists of 100,000,000 shares of common stock, par value
$0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. As of the
date of this prospectus, we had 12,567,226 shares of our common stock outstanding. There are no
shares of preferred stock outstanding.
We are a Delaware corporation, and were incorporated on July 24, 2006. We are the successor by
merger to Catalyst Pharmaceutical Partners, Inc., a Florida corporation, which was incorporated in
January 2002.
Each holder of common stock is entitled to one vote for each share held of record on all
matters presented to our stockholders, including the election of directors. In the event of our
liquidation, dissolution, or winding-up, the holders of common stock are entitled to share ratably
and equally in our assets, if any, that remain after paying all debts and liabilities and the
liquidation preferences of any outstanding preferred stock. The common stock has no preemptive or
cumulative rights and no redemption or conversion provisions.
Holders of our common stock are entitled to receive dividends if, as, and when declared by our
Board of Directors out of funds legally available therefor, subject to the dividend and liquidation
rights of any preferred stock that may be issued and outstanding, all subject to any dividend
restrictions in our credit facilities. No dividend or other distribution (including redemptions and
repurchases of shares of capital stock) may be made, if after giving effect to such distribution,
we would not be able to pay our debts as they come due in the usual course of business, or if our
total assets would be less than the sum of our total liabilities plus the amount that would be
needed at the time of a liquidation to satisfy the preferential rights of any holders of preferred
stock.
Provisions of the Certificate and Bylaws
A number of provisions of our certificate of incorporation and bylaws concern matters of
corporate governance and the rights of stockholders. Certain of these provisions, as well as the
ability of our board of directors to issue shares of preferred stock and to set the voting rights,
preferences and other terms thereof, may be deemed to have an anti-takeover effect and may
discourage takeover attempts not first approved by the board of directors (including takeovers
which certain stockholders may deem to be in their best interests). To the extent takeover attempts
are discouraged, temporary fluctuations in the market price of the common stock, which may result
from actual or rumored takeover attempts, may be inhibited. These provisions, together with the
classified board of directors (which we are proposing to declassify) and the ability of the board
to issue preferred stock without further stockholder action, also could delay or frustrate the
removal of incumbent directors or the assumption of control by stockholders, even if such removal
or assumption would be beneficial to our stockholders. These provisions also could discourage or
make more difficult a merger, tender offer or proxy contests, even if they could be favorable to
the interests of stockholders, and could potentially depress the market price of the common stock.
The board of directors believes that these provisions are appropriate to protect our interest and
the interests of our stockholders.
Issuance of Rights. The certificate authorized the board of directors to create and
issue rights (the rights) entitling the holders thereof to purchase from us shares of capital
stock or other securities. The
6
times at which, and the terms upon which, the rights are to be issued may be determined by the
board of directors and set forth in the contracts or instruments that evidence the rights. The
authority of the board of directors with respect to the rights includes, but is not limited to, the
determination of (1) the initial purchase price per share of the capital stock or other securities
of Catalyst Pharmaceutical Partners, Inc. to be purchased upon exercise of the rights, (2)
provisions relating to the times at which and the circumstances under which the rights may be
exercised or sold or otherwise transferred, either together with or separately from, any other
securities of Catalyst Pharmaceutical Partners, Inc., (3) antidilutive provisions which adjust the
number or exercise price of the rights or amount or nature of the securities or other property
receivable upon exercise of the rights, (4) provisions which deny the holder of a specified
percentage of the outstanding securities of Catalyst Pharmaceutical Partners, Inc. the right to
exercise the rights and/or cause the rights held by such holder to become void, (5) provisions
which permit Catalyst Pharmaceutical Partners, Inc. to redeem the rights and (6) the appointment of
a rights agent with respect to the rights.
Meetings of Stockholders. The bylaws provide that a special meeting of stockholders
may be called only by the board of directors unless otherwise required by law. The bylaws provide
that only those matters set forth in the notice of the special meeting may be considered or acted
upon at that special meeting, unless otherwise provided by law. In addition, the bylaws set forth
certain advance notice and informational requirements and time limitations on any director
nomination or any new business which a stockholder wishes to propose for consideration at an annual
meeting of stockholders.
No Stockholder Action by Written Consent. The certificate provides that any action
required or permitted to be taken by our stockholders at an annual or special meeting of
stockholders must be effected at a duly called meeting and may not be taken or effected by a
written consent of stockholders in lieu thereof.
Amendment of the Certificate. The certificate provides that an amendment thereof must
first be approved by a majority of the board of directors and (with certain exceptions) thereafter
approved by the holders of a majority of the total votes eligible to be cast by holders of voting
stock with respect to such amendment or repeal; provided, however, that the affirmative vote of 80%
of the total votes eligible to be cast by holders of voting stock, voting together as a single
class, is required to amend provisions relating to the establishment of the board of directors and
amendments to the certificate.
Amendments of Bylaws. The certificate provides that the board of directors or the
stockholders may amend or repeal the bylaws. Such action by the board of directors requires the
affirmative vote of a majority of the directors then in office. Such action by the stockholders
requires the affirmative vote of the holders of at least two-thirds of the total votes eligible to
be cast by holders of voting stock with respect to such amendment or repeal at an annual meeting of
stockholders or a special meeting called for such purposes, unless the board of directors
recommends that the stockholders approve such amendment or repeal at such meeting, in which case
such amendment or repeal shall only require the affirmative vote of a majority of the total votes
eligible to be cast by holders of voting stock with respect to such amendment or repeal.
Certain Anti-Takeover Matters
We are subject to the provisions of Section 203 of the Delaware General Corporation Law, or
Delaware law, regulating corporate takeovers. In general, these provisions prohibit a Delaware
corporation from engaging in any business combination with any interested stockholders for a period
of three years following the date that the stockholder became an interested stockholder, unless:
7
|
|
either the business combination or the transaction that resulted in the stockholder becoming
an interested stockholder is approved by our board of directors before the date the interested
stockholder attained that status; |
|
|
|
upon consummation of the transaction that resulted in the stockholder becoming an
interested stockholder, the interested stockholder owned at least 85% of the voting stock of
the corporation outstanding at the time the transaction commenced, excluding for purposes of
determining the voting stock outstanding (but not the outstanding voting stock owned by the
interested stockholder) those shares owned (i) by persons who are directors and also officers
and (ii) employee stock plans in which employee participates do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender
or exchange offer; or |
|
|
|
on or after that date, the business combination is approved by our board of directors and
authorized at a meeting of stockholders, and not by written consent, by at least two-thirds of
the outstanding voting stock that is not owned by the interested stockholder. |
Section 203 defines business combination to include the following:
|
|
any merger or consolidation involving the corporation and the interested stockholder; |
|
|
|
any sale, transfer, pledge or other disposition of 10% or more of the assets of the
corporation involving the interested stockholder; |
|
|
|
subject to certain exceptions, any transaction that results in the issuance or transfer by
the corporation of any stock of the corporation to the interested stockholder; |
|
|
|
any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned
by the interested stockholder; or |
|
|
|
the receipt by the interested stockholder of the benefit of any loans, advances,
guarantees, pledges or other financial benefits provided by or through the corporation. |
In general, Section 203 defines an interested stockholder as any entity or person beneficially
owning 15% or more of the outstanding voting stock of the corporation and any entity or person
affiliated with or controlling or controlled by any of these entities or persons.
A Delaware corporation may opt out of this provision either with an express provision in its
original certificate of incorporation or in an amendment to its certificate of incorporation or
bylaws approved by its stockholders. However, we have not opted out of this provision. The
statute could prohibit or delay mergers or other takeover or change in control attempts and,
accordingly, may discourage attempts to acquire us.
Limitation of Liability and Indemnification Matters
Our certificate of incorporation limits the liability for monetary damages for breach of
fiduciary duty by members of our Board of Directors, except for liability that cannot be eliminated
under Delaware law. Under Delaware law, our directors have a fiduciary duty to us which is not
eliminated by this provision in our certificate of incorporation. In addition, each of our
directors is subject to liability under Delaware law for breach of their duty of loyalty for acts
or omissions which are found by a court of
8
competent jurisdiction to be not in good faith or which involve intentional misconduct or knowing
violations of law for actions leading to improper personal benefit to the director and for payments
of dividends or approval of stock repurchases or redemptions that are prohibited by Delaware law.
This provision does not affect our directors responsibilities under any other laws, such as
federal securities laws.
Delaware law provides that the directors of a company will not be personally liable for
monetary damages for breach of their fiduciary duty as directors, except for liability for any of
the following:
|
|
|
any breach of a directors duty of loyalty to us or our stockholders; |
|
|
|
|
acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law; |
|
|
|
|
unlawful payment of dividends or unlawful stock repurchases or redemptions; or |
|
|
|
|
any transaction from which the director derived an improper personal benefit. |
Delaware law provides that the indemnification permitted thereunder shall not be deemed
exclusive of any other rights to which our directors and officers may be entitled to under our
bylaws, any agreement, a vote of stockholders or otherwise. Our certificate of incorporation and
bylaws eliminate the personal liability of directors to the maximum extent permitted by Delaware
law. In addition, our certificate of incorporation and bylaws provide that we may fully indemnify
any person who is or was a party to or is threatened to be made a party to any threatened, pending
or completed action, suit of proceeding (whether civil, criminal, administrative or investigative)
by reason of the fact that such person is or was one of our directors, officers, employees or other
agents, against expenses (including attorneys fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred by such person in connection with such action, suit or
proceeding.
Listing
Our common stock is listed on the Nasdaq Global Market and trades under the symbol CPRX.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Continental Stock Transfer & Trust
Company. They are located at 17 Battery Park, 8th Floor, New York, New York 10004. They
can be reached via telephone at (212) 509-4000.
9
PLAN OF DISTRIBUTION
We may sell the securities from time-to-time pursuant to underwritten public offerings,
negotiated transactions, block trades or a combination of these methods. We may sell the securities
(1) through underwriters or dealers, (2) through agents, and/or (3) directly to one or more
purchasers. However, in any given 12-month period, we may only sell securities hereunder with a value of up to one third of our public
float (the market value of our common stock held by non-affiliates). We may distribute the securities from time to time in one or more transactions at:
|
|
|
a fixed price or prices, which may change; |
|
|
|
|
market prices prevailing at the time of sale; |
|
|
|
|
prices relating to the prevailing market prices; |
|
|
|
|
varying prices determined at the time of sale; or |
|
|
|
|
negotiated prices. |
The applicable prospectus supplement with respect to a particular offering of securities will
describe the terms of the offering of the securities, including:
|
|
|
the name or names of any underwriters, and if required, any dealers or agents; |
|
|
|
|
the purchase price of the securities and the proceeds we will receive from the sale; |
|
|
|
|
any underwriting discounts and other items constituting underwriters compensation; |
|
|
|
|
any discounts or concessions allowed or reallowed or paid to dealers; and |
|
|
|
|
any securities exchange or market on which the securities may be listed. |
We may solicit directly offers to purchase the securities being offered by this prospectus. We
may also designate agents to solicit offers to purchase the securities from time to time. We will
name in a prospectus supplement any agent involved in the offer or sale of our securities.
If we utilize a dealer in the sale of the securities being offered by this prospectus, we will
sell the securities to the dealer, as principal. The dealer may then resell the securities to the
public at varying prices to be determined by the dealer at the time of resale. If we utilize an
underwriter in the sale of the securities being offered by this prospectus, we will execute an
underwriting agreement with the underwriter at the time of sale and we will provide the name of any
underwriter in the prospectus supplement which the underwriter will use to make resales of the
securities to the public. In connection with the sale of the securities, we, or the purchasers of
securities for whom the underwriter may act as agent, may compensate the underwriter in the form of
underwriting discounts or commissions. The underwriter may sell the securities to or through
dealers, and the underwriter may compensate those dealers in the form of discounts, concessions or
commissions.
With respect to underwritten public offerings, negotiated transactions and block trades, we
will provide in the applicable prospectus supplement any compensation we pay to underwriters,
dealers or agents in connection with the offering of the securities, and any discounts, concessions
or commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents
participating in the distribution of the securities may be deemed to be underwriters within the
meaning of the Securities Act
10
of 1933, as amended, and any discounts and commissions received by them and any profit realized by
them on resale of the securities may be deemed to be underwriting discounts and commissions. We may
enter into agreements to indemnify underwriters, dealers and agents against civil liabilities,
including liabilities under the Securities Act, or to contribute to payments they may be required
to make in respect thereof.
To facilitate the offering of securities, certain persons participating in the offering may
engage in transactions that stabilize, maintain or otherwise affect the price of the securities.
This may include overallotments or short sales of the securities, which involve the sale by
persons participating in the offering of more securities than we sold to them. In these
circumstances, these persons would cover such overallotments or short positions by making
purchases in the open market or by exercising their overallotment option. In addition, these
persons may stabilize or maintain the price of the securities by bidding for or purchasing
securities in the open market or by imposing penalty bids, whereby selling concessions allowed to
dealers participating in the offering may be reclaimed if securities sold by them are repurchased
in connection with stabilization transactions. The effect of these transactions may be to
stabilize or maintain the market price of the securities at a level above that which might
otherwise prevail in the open market. These transactions may be discontinued at any time.
The underwriters, dealers and agents may engage in other transactions with us, or perform
other services for us, in the ordinary course of their business.
LEGAL MATTERS
Certain legal matters in connection with any offering of securities made by this prospectus
will be passed upon for us by Akerman Senterfitt, Miami, Florida.
EXPERTS
The financial statements contained in the Annual Report on Form 10-K for the year ended
December 31, 2007 incorporated by reference in this Prospectus have been audited by Grant Thornton
LLP, independent registered public accountants, as indicated in their report with respect thereto,
and is included herein in reliance upon the authority of said firm as experts in accounting and
auditing in giving said report.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We file annual, quarterly and special reports, proxy statements and other information with the
SEC. Our SEC filings are available to the public over the SECs website at
http://www.sec.gov. You may also read and copy any document we file at the SECs Public
Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at (800) SEC0330
for further information on the operating rules and procedures for the public reference room.
This prospectus does not contain all of the information included in the registration
statement. We have omitted certain parts of the registration statement in accordance with the rules
and regulations of the SEC. For further information, we refer you to the registration statement,
including its exhibits and schedules. Statements contained in this prospectus and any accompanying
prospectus supplement about the provisions or contents of any contract, agreement or any other
document referred to are not necessarily complete. Please refer to the actual exhibit for a more
complete description of the matters involved.
11
INCORPORATION BY REFERENCE
The SEC allows us to incorporate by reference information into this prospectus, which means
that we can disclose important information to you by referring you to another document filed
separately with the SEC. The information incorporated by reference is deemed to be a part of this
prospectus, except for any information superseded by information in this prospectus or by any
information in a prospectus supplement accompanying this prospectus.
The following documents filed with the SEC are incorporated by reference in this prospectus:
|
1. |
|
Our Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC
on March 25, 2008; |
|
|
2. |
|
Our Proxy Statement for our Annual Meeting of Stockholders to be held on June 18, 2008,
filed with the SEC on April 29, 2008; |
|
|
3. |
|
Our Quarterly Report on Form 10-Q for the three months ended March 31, 2008, filed with
the SEC on May 15, 2008; |
|
|
4. |
|
Our description of our common stock contained in our Registration Statement on Form
8-A, filed with the SEC on September 29, 2006, along with Amendment No. 1 thereto, filed
with the SEC on October 18, 2006; and |
|
|
5. |
|
All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and
15(d) of the Exchange Act, from the date of filing of such documents, before the filing of a
post-effective amendment to this Registration Statement which indicates that all securities offered
hereunder have been sold or which deregisters all securities then remaining unsold.
|
You may obtain a copy of any of these documents at no cost by requesting them from us or by
writing or calling: Catalyst Pharmaceutical Partners, Inc., 355 Alhambra Circle, Suite 1370, Coral
Gables, Florida, 33134, Attn: Investor Relations, or by calling (305) 529-2522. Copies of each of
these filings are also available for no cost on our website, http://www.catalystpharma.com,
or on the SECs web site, http://www.sec.gov.
12
PART II
INFORMATION NOT REQUIRED IN THIS PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The following table sets forth all expenses to be paid by the registrant, other than
underwriting discounts and commissions, in connection with this offering. All amounts shown are
estimates except for the registration fee.
|
|
|
|
|
SEC registration fee |
|
$ |
1,179 |
|
Legal fees and expenses |
|
|
25,000 |
|
Accounting fees and expenses |
|
|
25,000 |
|
Miscellaneous expenses |
|
|
8,821 |
|
|
|
|
|
Total |
|
$ |
60,000 |
|
|
|
|
|
Item 15. Indemnification of Directors and Officers
Section 145 of the Delaware General Corporation Law provides for the indemnification of
officers, directors, and other corporate agents in terms sufficiently broad to indemnify such
persons under certain circumstances for liabilities (including reimbursement for expenses incurred)
arising under the Securities Act. The registrants Restated Certificate of Incorporation and the registrants Amended
and Restated Bylaws provide for indemnification of the registrants directors, officers, employees
and other agents to the extent and under the circumstances permitted by the Delaware General
Corporation Law. The registrant has also entered into agreements with its directors and officers that will require
the registrant, among other things, to indemnify them against certain liabilities that may arise
by reason of their status or service as directors or officers to the fullest extent not prohibited
by law.
Item 16. Exhibits
(a) Exhibits
|
|
|
Exhibit No. |
|
Description of Exhibit |
|
|
|
3.1
|
|
Certificate of Incorporation (1) |
|
|
|
3.2
|
|
Amendment to Certificate of Incorporation (1) |
|
|
|
3.3
|
|
By-laws (1) |
|
|
|
4.1
|
|
Specimen stock certificate for common stock (1) |
|
|
|
5.1
|
|
Opinion of Akerman Senterfitt |
|
|
|
23.1
|
|
Consent of Grant Thornton LLP |
|
|
|
23.2
|
|
Consent of Akerman Senterfitt (included in Exhibit 5.1) |
|
|
|
24.1
|
|
Power of Attorney (included on signature page of this Registration Statement) |
|
|
|
(1) |
|
Filed by reference to the Companys Registration Statement on Form S-1 (File
No. 333-136039) |
II-1
Item 17. Undertakings
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a posteffective
amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the
registration statement (or the most recent posteffective amendment thereof) which, individually or
in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and
any deviation from the low or high end of the estimated maximum offering range may be reflected in
the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in
the maximum aggregate offering price set forth in the Calculation of Registration Fee table in
the effective registration statement; and
(iii) To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in
the registration statement;
provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do
not apply if the registration statement is on Form S3 and the information required to be included
in a posteffective amendment by those paragraphs is contained in periodic reports filed with or
furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or
15(d) of the Securities Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference
in the registration statement, or is contained in a form of prospectus filed pursuant to Rule
424(b) (§ 230.424(b) of this chapter) that is part of the registration statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such
posteffective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(3) To remove from registration by means of a posteffective amendment any of the securities
being registered which remain unsold at the termination of the offering.
(4) That, for the purpose of determining liability under the Securities Act of 1933 to any
purchaser:
(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be
part of the registration statement as of the date the filed prospectus was deemed part of and
included in the registration statement; and
(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as
part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to
Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required
II-2
by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in
the registration statement as of the earlier of the date such form of prospectus is first used
after effectiveness or the date of the first contract of sale of securities in the offering
described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of
the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that
is a part of the registration statement will, as to a purchaser with a time of contract sale prior
to such effective date, supersede or modify any statement that was made in the registration
statement or prospectus that was a part of the registration statement or made in any such document
immediately prior to such effective date.
(5) That, for the purpose of determining liability of the registrant under the Securities Act
to any purchaser in the initial distribution of securities, the undersigned registrant undertakes
that in a primary offering of securities of the undersigned registrant pursuant to this
registration statement, regardless of the underwriting method used to sell the securities to the
purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered
to offer or sell such securities to such purchaser:
(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the
offering required to be filed pursuant to Rule 424 (§ 230.424 of this chapter);
(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned registrant;
(iii) The portion of any other free writing prospectus relating to the offering containing
material information about the undersigned registrant or its securities provided by or on behalf of
the undersigned registrant; and
(iv) Any other communication that is an offer in the offering made by the undersigned
registrant to the purchaser.
(b) The undersigned registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act, each filing of the registrants annual report pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act and (and, where applicable, each filing of an
employee benefit plans annual report pursuant to Section 15(d) of the Securities Exchange Act) that is incorporated by reference
in the registration statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be
permitted to directors, officers and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the
II-3
registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.
(d) The undersigned registrant hereby undertakes that:
(1) For purposes of determining any liability under the Securities Act, the information
omitted from the form of prospectus filed as part of this registration statement in reliance upon
Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1)
or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective.
(2) For the purpose of determining any liability under the Securities Act, each posteffective
amendment that contains a form of prospectus shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant
certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-3 and has duly caused this Registration Statement to be signed on behalf of the
undersigned, thereunto authorized, in the city of Coral Gables, State
of Florida, on the 2nd day of
June, 2008.
|
|
|
|
|
|
CATALYST PHARMACEUTICAL PARTNERS, INC.
|
|
|
By: |
/s/ Patrick J. McEnany
|
|
|
|
Patrick J. McEnany |
|
|
|
Chairman, President and CEO |
|
|
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints Patrick J. McEnany
and Jack Weinstein, and each of them, as his true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution for him and in his name, place, and stead, in any and
all capacities, to sign any or all amendments or supplements to this registration statement,
whether pre-effective or post-effective, including any subsequent registration statement for the
same offering which may be filed under Rule 462(b) under the Securities Act of 1933, as amended, to
file the same with all exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of
them, full power and authority to do and perform each and every act and thing necessary or
appropriate to be done with respect to this registration statement or any amendments or supplements
hereto in the premises, as fully to all intents and purposes as he might or could do in person,
hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them, or this
or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has
been signed by the following persons, in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Patrick J. McEnany
|
Patrick J. McEnany
|
|
Chairman of the Board of Directors, President and
Chief Executive Officer
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Jack Weinstein
|
|
Vice President, Treasurer and Chief Financial Officer
|
|
June 2, 2008 |
Jack Weinstein
|
|
(Principal Financial Officer) |
|
|
|
|
|
|
|
/s/ Alicia Grande
|
Alicia Grande
|
|
Corporate Controller/Chief
Accounting Officer
(Principal Accounting Officer) |
|
June 2, 2008 |
/s/ Hubert E. Huckel, M.D.
|
Hubert E. Huckel, M.D.
|
|
Director |
|
June 2, 2008 |
II-5
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Charles B. OKeeffe
|
|
Director
|
|
June 2, 2008 |
Charles B. OKeeffe
|
|
|
|
|
|
|
|
|
|
/s/
Philip H. Coelho
|
|
Director
|
|
June 2, 2008 |
Philip H. Coelho
|
|
|
|
|
|
|
|
|
|
/s/ David S. Tierney, M.D.
|
|
Director
|
|
June 2, 2008 |
David S. Tierney, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Milton J. Wallace
|
|
Director
|
|
June 2, 2008 |
Milton J. Wallace
|
|
|
|
|
II-6
EX-5.1 Opinion of Akerman Seterfitt LLP.
Exhibit
5.1
Fort Lauderdale
Jacksonville
Los Angeles
Madison
Miami
New York
Orlando
Tallahassee
Tampa
Tysons Corner
Washington, DC
West Palm Beach
One Southeast Third Avenue
25th Floor
Miami, Florida 33131-1714
www.akerman.com
305 374 5600 tel 305 374 5095 fax
June 2, 2008
Catalyst Pharmaceutical Partners, Inc.
355 Alhambra Circle
Suite 1370
Coral Gables, FL 33134
|
|
|
Re: |
|
Catalyst Pharmaceutical Partners, Inc. Registration Statement on Form S-3 |
Ladies and Gentlemen:
We have acted as counsel to Catalyst Pharmaceutical Partners, Inc., a Delaware corporation
(the Company), in connection with the preparation and filing with the Securities and Exchange
Commission (the Commission) under the Securities Act of 1933, as amended (the Securities Act)
of a registration statement on Form S-3 (the Registration Statement) relating to the offering
from time to time, together or separately in one or more series (if applicable), of shares of the
Companys common stock, par value $0.001 per share (the Common Stock). The Common Stock offered
hereunder is to be offered by the Company on a delayed or continuous basis pursuant to the
provisions of Rule 415 under the Securities Act.
In connection with this opinion, we have examined such corporate records, documents,
instruments, certificates of public officials and of the Company and such questions of law we have
deemed necessary for the purpose of rendering the opinions set forth herein. We have also examined
the Registration Statement. In such examination, we have assumed the genuineness of all signatures
and the authenticity of all items submitted to us as originals and the conformity with originals of
all items submitted to us as copies.
June 2, 2008
Page 2
The opinions hereinafter expressed are subject to the following qualifications and exceptions:
|
(a) |
|
The effect of bankruptcy, insolvency, reorganization, arrangement, moratorium or other
similar laws relating to or affecting the rights of creditors generally, including, without
limitation, laws relating to fraudulent transfers or conveyances, preferences and equitable
subordination, and without limiting the generality of the foregoing qualification; |
|
|
(b) |
|
limitations imposed by general principles of equity upon the availability of equitable
remedies and the effect of judicial decisions which have held that certain provisions are
unenforceable where their enforcement would violate the implied covenant of good faith and
fair dealing, or which would be commercially unreasonable, or where their breach is not
material; |
|
|
(c) |
|
we express no opinion as to the enforceability of any provisions of any agreement
providing for indemnification or contribution, to the extent such indemnification or
contribution is against public policy; |
|
|
(d) |
|
except to the extent encompassed by an opinion set forth below with respect to the
Company, the effect on the opinions expressed herein of (i) the compliance or
non-compliance of any party to any agreement with any law, regulation or order applicable
to it, or (ii) the legal or regulatory status or the nature of the business of any such
party; and |
|
|
(e) |
|
our opinion is based upon current statutes, rules, regulations, cases and official
interpretative opinions, and it covers certain items that are not directly or definitively
addressed by such authorities. |
Based on the foregoing, and subject to the further assumptions and qualifications set forth
below, it is our opinion that the Common Stock, when authorized, issued and sold by the Company for
an amount per share not less than the par value thereof and in the manner described in the
Registration Statement and any applicable prospectus supplement relating thereto, in accordance
with any underwriting agreement or purchase agreement, and in accordance with the resolutions to be
adopted by the Board of Directors of the Company, will be duly and validly issued, fully paid and
nonassessable.
Insofar as the foregoing opinions relate to the validity, binding effect or enforceability of
any agreement or obligation of the Company, we have assumed that the Company and each other party
to such agreement or obligation has satisfied or, prior to the issuance of the Securities, will
satisfy those legal requirements that are applicable to it to the extent necessary to make such
agreement or obligation enforceable against it.
In rendering the opinions expressed above, we have further assumed that (i) the Common Stock
will be offered, sold and delivered to, and paid for by, the purchasers thereof at the price
June 2, 2008
Page 3
specified in, and in accordance with the terms of, an agreement or agreements duly authorized,
executed and delivered by the parties thereto, (ii) the Company will authorize the offering and
issuance of the Common Stock and will authorize, execute and deliver any and all documents
contemplated thereby or by the Registration Statement or any applicable prospectus supplement
relating thereto, and will take any other appropriate additional corporate action with
respect thereto, (iii) certificates, if required, representing the Common Stock will be duly
executed and delivered and, to the extent required by any applicable agreement, duly authenticated
and countersigned and (v) a sufficient number of shares of Common Stock will be
authorized and available for issuance and the consideration therefor will not be less than the par
value of the shares of the Common Stock.
We express no opinion as to matters governed by laws of any jurisdiction other than the
General Corporation Law of the State of Delaware, including the applicable provisions of the
Delaware Constitution and the reported judicial decisions interpreting such law, and the federal
laws of the United States of America, as in effect on the date hereof.
We hereby consent to the use of our name under the heading Legal Matters in the Registration
Statement to be filed by the Company with the Commission. We further consent to your filing a copy
of this opinion as Exhibit 5.1 to the Registration Statement. In giving such permission, we do not
admit hereby that we come within the category of persons whose consent is required under Section 7
of the Securities Act, or the rules and regulations of the Commission thereunder. We disclaim any
undertaking to advise you of any subsequent changes of the facts stated or assumed herein or any
subsequent changes in applicable law.
Sincerely,
/s/ Akerman Senterfitt
AKERMAN SENTERFITT
EX-23.1 Consent of Grant Thornton LLP
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our report dated March 11, 2008 with respect to the financial statements of Catalyst
Pharmaceutical Partners, Inc. (which report expressed an unqualified opinion and contains an
explanatory paragraph relating to the adoption of Financial Accounting Standards Board
Interpretation No. 48, Accounting for Uncertainty in Income Taxes in 2007 and Financial Accounting
Standards Board Statement No. 123(R), Share-Based Payment in 2006) which is included in the Annual
Report on Form 10-K for the year ended December 31, 2007 incorporated by reference in this
Registration Statement. We consent to the incorporation by reference in the Registration Statement
of the aforementioned report and to the use of our name as it appears under the caption Experts.
GRANT THORNTON LLP
Miami, Florida
May 28, 2008